Edwards Lifesciences has received approval from the US Food and Drug Administration (FDA) for its EVOQUE tricuspid valve replacement system, a transcatheter therapy, for treating TR.

The system has been designed for patients with symptomatic severe TR who have not responded to optimal medical therapy and for whom valve replacement is considered appropriate by a heart team.

It features a nitinol self-expanding frame, an intra-annular sealing skirt, and tissue leaflets crafted from Edwards Lifesciences’s bovine pericardial tissue.

To be available in three sizes, the valve will be delivered through a low-profile transfemoral 28F system.

Edwards Lifesciences transcatheter mitral and tricuspid therapies corporate vice-president Daveen Chopra said: “Edwards has a long history of leading innovation and pioneering new therapies to address the unmet needs of patients with structural heart disease.

“We are grateful for the strong collaboration with clinicians all over the world who contributed to the EVOQUE system now being available through FDA’s Breakthrough Pathway to provide a treatment option to the many patients in the US suffering from tricuspid valve disease.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

TRISCEND II trial, a six-month long study, showcased the system’s success, with results presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023.

The trial demonstrated the EVOQUE system’s superiority over optimal medical therapy alone, achieving all primary endpoints.

Significant reductions or eliminations of TR and sustained quality of life improvements were noted, alongside a favourable risk-benefit profile.

Further data from the TRISCEND II trial, involving 318 out of 392 randomised patients who completed a one-year visit, indicated positive trends in the device group versus the control group.

The primary composite endpoints included all-cause mortality, heart failure hospitalisation, tricuspid intervention and improvements in the Kansas City Cardiomyopathy Questionnaire (KCCQ), New York Heart Association (NYHA), and six-minute walk distance (6MWD).

The EVOQUE system also received CE mark approval last year, claiming to be the first transcatheter valve replacement therapy globally approved for the treatment of TR.